UCSF Navigation Bar

UCSF Departments of Pathology & Laboratory Medicine Home Page

Lab Manual for UCSF Clinical Laboratories

Lab Manual for SFGH

Internal Resources

Alan H.B. Wu, PhD

Research and Clinical Interests

My area of research is focused on “personalized therapeutics,” i.e., the use of biomarkers to determine proper selection and dosing of drugs to maximize efficacy and minimize adverse reactions. Many future drugs will require biomarker testing prior to use on individual patients and clinical trials are needed to validate their use. In the area of pharmacogenomics, we are interested in drug dosing studies for warfarin, irinotecan, tamoxifen, phenytoin and lipid lowering drugs. We are also performing research on validating novel protein markers for cardiovascular diseases such as stroke, acute coronary syndromes and heart failure.

Selected Publications

  • Rodda L, Volk J, Moffatt E, Williams CM, Lynch K, Wu AHB. Intraosseous fluid as alternative biological specimen in postmortem toxicology. J Anal Toxicol 2017, doi.org/10.1093/jat/bkx096.
  • Wu AHB, Christenson RH, Greene DN, Jaffe AS, Kavsak PA, Ordonez-Llanos J, Apple FS. Clinical laboratory practice recommendations for use of cardiac troponin in acute coronary syndrome: expert opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardio Bio-markers of the International Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem 2018;64(4):645-655.
  • Li P, Enea NS, Zuk R, Tan H, Wu AHB, Jaffe AS. Performance characteristics of a high-sensitivity cardiac troponin assay using plasma and whole blood samples. Clin Biochem 2017;50:1249-52.
  • Estis J, Wu AHB, Todd J, Bishop J, Kavsak PA. Comprehensive age and sex 99th percentile reference intervals for a high-sensitivity cardiac troponin I assay. Clin Chem 2017, 62: DOI: 10.1373/clinchem.2017.276972.
  • Vo KT, Horng H Li K, Ho RY, Wu AHB, Lynch KL, Smollin CG. Cannabis intoxication case series: the dangers of edibles containing tetrahydrocannabinol. 2017; https://doi.org/10.1016/j.annemergmed.2017.09.008.
  • Kavsak PA, Jaffe AS, Green D, Christenson R, Wu AHB. Total analytic error for low cardiac troponin concentrations (<10 ng/L) by use of a high-sensitivity cardiac troponin assay. Clin Chem 2017;63:1043-5.
  • Thoren K, Basi B,Delgado J, Wu AHB, Lynch KL. Quantitation of infliximab and detection of anti-drug antibodies in serum using surface plasmon resonance. J Appl Lab Med. 2017. DOI: 10.1373/jalm.2017.024380.
  • Van Wijk XMR, Vittinghoff E, Wu AHB, Lynch KL, Riley ED. Cocaine use is associated with elevated ST2 concentrations in the absence of known clinical cardiovascular disease. Clin Biochem 2017;50:791-3.

Selected Awards

  • 2002 American Assoc for Clinical Chemistry Outstanding Contributions to Education Award
  • 2005 IVD Technology's Top Ten Persons in the IVD Industry
  • 2005 AACC Connecticut Valley Section, Seligson-Golden Award
  • 2006 Meyer Bodanski Visiting Professor of Pathology, University of Texas Medical Branch

Additional Information

Alan H.B. Wu, PhD
  • Professor Laboratory Medicine; Chief, Clinical Chemistry Laboratory, SFGH; Chief, Clinical Pharmacogenomics Laboratory, UCSF
  • Laboratory Medicine
  • Clinical Chemistry

Specialty Area

  • Cardiac biomarkers
  • Analytical and toxicology
  • Pharmacogenomics

Contact Information

Mailing/Shipping Address:

  • Zuckerberg San Francisco General Hospital & Trauma Center
  • 1001 Potrero Ave., Room 2M27
  • San Francisco, CA 94110

Other UCSF Organizational Association(s)

Graduate faculty

  • Pharmaceutical Science and Pharmacogenomics

Hospital Affiliation(s)

  • San Francisco General Hospital & Trauma Center
UCSF home page UCSF home page About UCSF Search UCSF UCSF Medical Center